DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
FLYSYN
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Tyrosine-protein kinase receptor FLT3 inhibitor
FLYSYN
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KHK-2866
1
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Proheparin-binding EGF-like growth factor inhibitor
KHK-2866
×
Maximum Phase:
1
First Approval:
None
UNII:
111EN0IJ7C
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PIMURUTAMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell
Unknown
PIMURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
5V1Y8T4RB6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SONTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 other
SONTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PLAMOTAMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell
Unknown
PLAMOTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
5ENX424FNF
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CEVOSTAMAB
1
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma
Unknown
CEVOSTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7598
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RG-7598
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMC-CS4
1
Antibody
Investigational
Unknown
Unknown
Pancreatic Neoplasms; Neoplasms
Macrophage colony stimulating factor receptor inhibitor
IMC-CS4
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PAVURUTAMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PAVURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VAPALIXIMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
VAPALIXIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
M1EGR25LBB
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-100
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TNX-100
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUPAM4
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
HUPAM4
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RHIGM12B7
1
Antibody
Investigational
Unknown
Unknown
Melanoma
Programmed cell death 1 ligand 2 cross-linking agent
RHIGM12B7
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RM-1929
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RM-1929
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BOS161721
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BOS161721
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRALUZATAMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PRALUZATAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELUVIXTAMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Unknown
ELUVIXTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CNTO-5825
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interleukin-13 inhibitor
CNTO-5825
×
Maximum Phase:
1
First Approval:
None
UNII:
JYB0ILB7HU
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PONSEGROMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
PONSEGROMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TIMOLUMAB
1
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
TIMOLUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
UJO03RO3K6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FORAVIRUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Glycoprotein inhibitor
FORAVIRUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
377VY97V7S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NARATUXIMAB EMTANSINE
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell
Leukocyte antigen CD37 binding agent
NARATUXIMAB EMTANSINE
×
Maximum Phase:
1
First Approval:
None
UNII:
WE1X5A83B9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MANELIMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MANELIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
U3OZ7HX207
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-191
1
Antibody
Investigational
Unknown
Unknown
Severe Combined Immunodeficiency
Stem cell growth factor receptor inhibitor
AMG-191
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANDORTUZUMAB VEDOTIN
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Metalloreductase STEAP1 binding agent
VANDORTUZUMAB VEDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
44OUQ00D1U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANTICTUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Pancreatic Neoplasms
Frizzled-1 antagonist
VANTICTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
88WBI2D80S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAMROTAMAB VEDOTIN
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Squamous Cell; Histiocytoma, Malignant Fibrous
Unknown
SAMROTAMAB VEDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
SY5HF6N5MB
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIRZOTAMAB CLEZUTOCLAX
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
MIRZOTAMAB CLEZUTOCLAX
×
Maximum Phase:
1
First Approval:
None
UNII:
TY49T0B03B
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLANVOTUMAB
1
Antibody
Investigational
Unknown
Unknown
Melanoma
5,6-dihydroxyindole-2-carboxylic acid oxidase other
FLANVOTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
ZNV4738BS6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EZABENLIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
EZABENLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CSL-360
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Interleukin-3 receptor subunit alpha inhibitor
CSL-360
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SIBROTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Fibroblast activation protein alpha binding agent
SIBROTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
552U6E1NIW
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EPITUMOMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
EPITUMOMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
3VD89OE565
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIIB-022
1
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms
Insulin-like growth factor I receptor inhibitor
BIIB-022
×
Maximum Phase:
1
First Approval:
None
UNII:
Y60655Y65T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-4212
1
Antibody
Investigational
Unknown
Unknown
Dermatitis, Atopic; Rhinitis, Allergic, Seasonal
Ig epsilon chain C region inhibitor
MEDI-4212
×
Maximum Phase:
1
First Approval:
None
UNII:
XK0D8BK5WY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
7
8
9
10
11
12
13
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA